Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
作者信息
Furst D E, Breedveld F C, Kalden J R, Smolen J S, Burmester G R, Emery P, Keystone E C, Schiff M H, van Riel P L C M, Weinblatt M E, Weisman M H
机构信息
David Geffen School of Medicine, UCLA - RM 32-59, 1000 Veteran Avenue, Los Angeles, CA 90025, USA.
出版信息
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii2-15. doi: 10.1136/ard.2006.061937.
Abstract
摘要
相似文献
1
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.《2006年关于治疗风湿性疾病生物制剂的最新共识声明》
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii2-15. doi: 10.1136/ard.2006.061937.
2
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.《2007年关于治疗风湿性疾病生物制剂的更新共识声明》
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430.
3
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.《2008年关于治疗风湿性疾病生物制剂的更新共识声明》
Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834.
4
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.《2011年关于治疗风湿性疾病生物制剂的更新共识声明》
Ann Rheum Dis. 2012 Apr;71 Suppl 2:i2-45. doi: 10.1136/annrheumdis-2011-201036.
5
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.《2005年关于生物制剂，特别是肿瘤坏死因子α（TNFα）阻断剂和白细胞介素-1受体拮抗剂（IL-1ra）治疗风湿性疾病的更新共识声明》
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv2-14. doi: 10.1136/ard.2005.044941.
6
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.《2010年关于治疗风湿性疾病生物制剂的更新共识声明》
Ann Rheum Dis. 2011 Mar;70 Suppl 1:i2-36. doi: 10.1136/ard.2010.146852.
7
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.2004年关于生物制剂（特别是肿瘤坏死因子α（TNFα）阻断剂和白细胞介素-1受体拮抗剂（IL-1ra））治疗风湿性疾病的更新共识声明。
Ann Rheum Dis. 2004 Nov;63 Suppl 2(Suppl 2):ii2-ii12. doi: 10.1136/ard.2004.029272.
8
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.《2012年关于治疗风湿性疾病生物制剂的更新共识声明》
Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii2-34. doi: 10.1136/annrheumdis-2013-203348.
9
[Biologicals in the treatment of rheumatic diseases].[生物制剂在风湿性疾病治疗中的应用]
Dtsch Med Wochenschr. 2006 Oct 13;131(41):2279-85. doi: 10.1055/s-2006-951364.
10
Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.阿巴西普及其在捷克共和国类风湿关节炎（RA）治疗中的应用——来自 ATTRA 登记处的数据。
Clin Rheumatol. 2013 Oct;32(10):1451-8. doi: 10.1007/s10067-013-2303-6. Epub 2013 Jun 2.
引用本文的文献
1
A Toolbox of Potential Immune-Related Therapies for Inflammatory Cardiomyopathy.用于炎症性心肌病的潜在免疫相关治疗的工具箱。
J Cardiovasc Transl Res. 2021 Feb;14(1):75-87. doi: 10.1007/s12265-020-10025-4. Epub 2020 May 21.
2
Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report.英夫利昔单抗治疗6个月期间的抗磷脂抗体：初步报告。
Med Sci Monit. 2014 Jul 16;20:1227-31. doi: 10.12659/MSM.890270.
3
Steroids Decrease Prevalence of Positive Tuberculin Skin Test in Rheumatoid Arthritis: Implications on Anti-TNF Therapies.类固醇降低类风湿关节炎患者结核菌素皮肤试验阳性率：对肿瘤坏死因子拮抗剂治疗的影响
Interdiscip Perspect Infect Dis. 2014;2014:430134. doi: 10.1155/2014/430134. Epub 2014 Feb 24.
4
Prefilled certolizumab pegol (Cimzia(®)) syringes for self-use in the treatment of rheumatoid arthritis.预充式赛妥珠单抗（希敏佳（®））注射器，供类风湿关节炎自我治疗使用。
Med Devices (Auckl). 2010;3:25-31. doi: 10.2147/mder.s7504. Epub 2010 Aug 10.
5
ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment.ELISPOT-IFN-γ assay 替代结核菌素皮肤试验用于检测风湿性疾病患者潜在结核分枝杆菌感染及其候选者的抗 TNF-α 治疗。
Clin Rheumatol. 2010 Oct;29(10):1135-41. doi: 10.1007/s10067-010-1532-1. Epub 2010 Jul 20.
6
Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections?英夫利昔单抗治疗银屑病关节炎患者李斯特菌心内膜炎：生物制剂治疗炎症性关节炎是否增加李斯特菌感染的发生率？
J Infect. 2010 May;60(5):386-96. doi: 10.1016/j.jinf.2010.02.009. Epub 2010 Feb 20.
7
Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database.接受生物治疗的类风湿关节炎患者群体队列中的基线合并症：来自澳大利亚风湿病协会数据库的数据。
Int J Rheumatol. 2009;2009:861481. doi: 10.1155/2009/861481. Epub 2009 Sep 1.
8
The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project.肿瘤坏死因子-α 阻滞剂的日常应用。一项奥地利共识项目。
Clin Rheumatol. 2010 Feb;29(2):167-74. doi: 10.1007/s10067-009-1304-y. Epub 2009 Nov 11.
9
Prevalence of positive ppd in a cohort of rheumatoid arthritis patients.类风湿关节炎患者队列中 ppd 阳性的患病率。
Rheumatol Int. 2010 Mar;30(5):613-6. doi: 10.1007/s00296-009-1027-z. Epub 2009 Jul 4.
10
Protein biochip array technology to monitor rituximab in rheumatoid arthritis.用于监测类风湿关节炎中利妥昔单抗的蛋白质生物芯片阵列技术。
Clin Exp Immunol. 2009 Mar;155(3):395-402. doi: 10.1111/j.1365-2249.2008.03804.x.
本文引用的文献
1
Etanercept and hepatitis C.依那西普与丙型肝炎
J Clin Rheumatol. 1999 Jun;5(3):179. doi: 10.1097/00124743-199906000-00015.
2
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.阿巴西普对甲氨蝶呤抵抗的活动性类风湿关节炎患者的疗效：一项随机试验。
Ann Intern Med. 2006 Jun 20;144(12):865-76. doi: 10.7326/0003-4819-144-12-200606200-00003.
3
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.利妥昔单抗用于尽管接受甲氨蝶呤治疗但仍患有活动性类风湿性关节炎患者的疗效和安全性：一项IIB期随机、双盲、安慰剂对照、剂量范围试验的结果
Arthritis Rheum. 2006 May;54(5):1390-400. doi: 10.1002/art.21778.
4
Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.韦格纳肉芽肿病依那西普试验中患者的实体恶性肿瘤
Arthritis Rheum. 2006 May;54(5):1608-18. doi: 10.1002/art.21869.
5
Etanercept: effective in the management of hidradenitis suppurativa.依那西普：对化脓性汗腺炎的治疗有效。
Br J Dermatol. 2006 Apr;154(4):726-9. doi: 10.1111/j.1365-2133.2005.07067.x.
6
Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.阿达木单抗可减轻活动性强直性脊柱炎的脊柱症状：一项为期52周的开放标签试验的临床和磁共振成像结果
Arthritis Rheum. 2006 Feb;54(2):678-81. doi: 10.1002/art.21563.
7
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.阿达木单抗（修美乐）在类风湿性关节炎患者全球临床试验及美国上市后监测中的安全性分析。
Ann Rheum Dis. 2006 Jul;65(7):889-94. doi: 10.1136/ard.2005.043166. Epub 2006 Jan 26.
8
The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications.肿瘤坏死因子α阻断对慢性关节炎患者抗核抗体谱的影响：生物学及临床意义
Lupus. 2005;14(12):931-7. doi: 10.1191/0961203305lu2240rr.
9
Safety of extended treatment with anakinra in patients with rheumatoid arthritis.类风湿关节炎患者使用阿那白滞素延长治疗的安全性。
Ann Rheum Dis. 2006 Aug;65(8):1006-12. doi: 10.1136/ard.2005.048371. Epub 2006 Jan 5.
10
The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.类风湿关节炎患者从英夫利昔单抗转换为依那西普以及从依那西普转换为英夫利昔单抗的有效性。
Clin Exp Rheumatol. 2005 Nov-Dec;23(6):795-800.
Zotero 插件